Encompass Health (EHC)
(Delayed Data from NYSE)
$94.50 USD
-0.23 (-0.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $94.48 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.50 USD
-0.23 (-0.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $94.48 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Here's Why Encompass Health (EHC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Encompass Health (EHC) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of an active expansion strategy and sufficient cash-generating abilities.
Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSM
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Encompass Health (EHC) Opens Second Hospital in Wisconsin
by Zacks Equity Research
The inpatient rehabilitation hospital's opening in Fitchburg, WI, was moved up from the initially scheduled first quarter of 2024.
Encompass Health (EHC) Opens Hospital to Boost Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Humana's (HUM) CenterWell Unit Plans Expansion in Indiana
by Zacks Equity Research
Humana's (HUM) CenterWell brand will open four senior-focused primary care centers across Indianapolis in order to address the unique needs of the area's senior population.
Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Encompass Health (EHC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Encompass Health (EHC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4%
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.
Down -9.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Encompass Health (EHC)
by Zacks Equity Research
Encompass Health (EHC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Encompass Health's (EHC) Q3 Earnings Beat on Discharge Growth
by Zacks Equity Research
Encompass Health's (EHC) Q3 results benefit from an increase in patient volumes and net patient revenue per discharge. Management currently projects adjusted EPS to be within $3.41-$3.52 for 2023.
Encompass Health (EHC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Encompass Health (EHC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Encompass Health (EHC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 11.69% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSM
Chemed (CHE) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 8.13% and 0.79%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Encompass Health (EHC) in Q3 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.
Encompass Health (EHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Encompass Health (EHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tenet Healthcare (THC) Rides on Strong Patient Volumes, Buyouts
by Zacks Equity Research
Tenet Healthcare (THC) gains from expanding patient admissions, diversified treatment network, acquisitions and robust cash-generating abilities.
Top Medical Stocks to Buy Amid Market Volatility
by Shaun Pruitt
While there is no guarantee that medical stocks will offer a hedge against market volatility, healthcare is essential even during economic uncertainty.